CClinicalTrials.gg
RecruitingNCT05913609Updated Nov 25, 2025

Safety and Effectiveness of the Yaari Extractor for Management of Shoulder Dystocia

An interventional study of Yaari Extractor in Shoulder Dystocia, sponsored by FetalEase Ltd.. Recruiting at 4 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-25.

Sponsored by FetalEase Ltd. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2023; still recruiting 2 years 10 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Prospective, multi-center, single arm with historical control, to verify the safety and effectiveness of the Yaari Extractor used by board certified or board eligible U.S. OB/GYN physicians in the management of shoulder dystocia.

02

Conditions studied

  • Shoulder Dystocia
03

In context

Lead sponsor

This is the only study on the registry with FetalEase Ltd. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Subject 18 years of age or older at time of consent.
  2. Subject planning on vaginal birth.
  3. Singleton pregnancy in vertex presentation.
  4. Full-term pregnancy having completed 37 weeks or more gestational weeks.
  5. Able and willing to provide written informed consent prior to enrollment.
  6. In the opinion of the Investigator, the subject has sufficient mental capacity to understand the informed consent form (ICF).
  7. Subject with fetus experiencing shoulder dystocia as defined by ACOG Practice Bulletin 178 "Shoulder dystocia is most commonly diagnosed as failure to deliver the fetal shoulder(s) with gentle downward traction on the fetal head, requiring additional maneuvers to effect delivery."

Exclusion criteria

Exclusion Criteria:

  1. Patients who have undergone attempted delivery using ancillary standard of care maneuvers, to include first-line maneuvers (McRoberts ± suprapubic pressure with downward traction on the fetal head), prior to use of the Yaari Extractor. (NOTE: Hyperflexion of the hips or legs is allowed prior to and during use of the Yaari Extractor.)
  2. Cesarean section is planned for the patient.
  3. Obstetric contraindications to vaginal birth.
  4. Subject carrying fetus with known significant chromosomal or structural anomalies.
  5. Clinically estimated fetal weight ≥5kg in non-diabetic subjects.
  6. Clinically estimated fetal weight ≥4.5kg in subjects with diabetes.
  7. Subject has any general health condition or systemic disease that may represent, in the opinion of the Investigator, a potential increased risk associated with device use or pregnancy.
  8. Bleeding disorders, such as thrombocytopenia, von Willebrand's disease, bleeding disorder currently using anticoagulation medication, etc.
  9. Any maternal disease or disorder that precludes the subject from pushing effectively.
  10. If the maternal cervix is not fully dilated.
  11. If the fetal head is not completely out of the birth canal.
  12. In the presence of a non-reducible nuchal cord.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Yaari Extractor group

    Prospective experimental arm

    Device: Yaari Extractor

  • No intervention
    Control group

    Historical control arm - retrospective review of medical records at the same study sites

Interventions

  • DeviceYaari Extractor

    The Yaari Extractor device is a single-use prescription device for neonatal extraction in deliveries that are complicated by shoulder dystocia. The Study Device consists of two curved, rigid plastic-coated metal Arms with Handles which are used for control of the device outside the body, and an elastic Engagement Element which conforms to the maternal and neonatal anatomy, and which is used for direct contact with the entrapped neonate within the birth canal.

06

What researchers measure

Primary outcomes

  1. Number of successful neonate deliveries with the Yaari Extractor device

    First Primary Effectiveness Endpoint

    Time frame: immediately after the intervention

  2. Time interval (minutes) from the diagnosis of the shoulder dystocia until the neonate's delivery

    Second Primary Effectiveness Endpoint

    Time frame: immediately after the intervention

  3. Maternal and neonatal adverse events

    Primary Safety Endpoint

    Time frame: through study completion, an average of 5 days

Secondary outcomes

  1. Ease of Use 5 point Likert scale User Questionnaire

    Secondary Effectiveness Endpoint

    Time frame: immediately after the intervention

07

Study locations

4 of 4 sites recruiting
  • University of Miami - Jackson Memorial
    Miami, Florida 33136, United States
    • Jemima Duroseau, BSN, RN, MPH · Contact · jxp431@med.miami.edu · 305-689-8010
    • Michael Paidas, MD · Principal investigator
    Recruiting
  • Rosemark WomenCare Specialist
    Idaho Falls, Idaho 83404, United States
    • Nora Ramirez · Contact · nramirez@rosemark.net · 208-557-2924
    • Jason Gundersen, MD · Principal investigator
    Recruiting
  • Unified Women's Clinical Research
    Winston-Salem, North Carolina 27103, United States
    Recruiting
  • Inova Fairfax Medical Campus
    Falls Church, Virginia 22042, United States
    • Fatima Sahar, MBBS · Contact · Sahar.Fatima@inova.org · 703-776-4600
    • Scott A Sullivan, MD · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05913609
Lead sponsor
FetalEase Ltd.
Responsible party
Sponsor
First posted
Jun 22, 2023
Start date
Nov 15, 2023
Primary completion
Nov 2026 (estimated)
Completion
Apr 2027 (estimated)
Last update
Nov 25, 2025

Study contacts

Ahava Stein
Contact
ahava@asteinrac.com
+972522346927

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion